SOURCE: Equity Markets Inc

August 01, 2011 09:00 ET

Shape Up for Industry Outlook - Research Report on Regeneron Pharmaceuticals, Inc. and AstraZeneca plc

MACAU--(Marketwire - Aug 1, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and AstraZeneca plc (NYSE: AZN). Full content and research is available at www.EquityMarketsInc.com/research.php.

Top considerations within today's market lies with the current status of the US debt ceiling. Despite the US National Gross Domestic Product beginning to move beyond high-watermark, marking a significant shift away from recessionary pressures; continued momentum relies upon inking of the most recent tentative non-default agreement within congress on or before August 2, 2011. The US Department of Commerce has confirmed growth within first quarter 2011, opening the strong possibility of companies within sub-sectors to experience organic revenue growth in the case of successful agreement.

No matter the outcome, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Fundamental positives in this area are provided by limited exposure to rising commodity costs. Although raw material cost increases will continue to pressure margins, well-positioned companies can leverage organic growth and general consolidation of product lines to sustain bottom-line growth. Market-wise investors are looking to build strong cash positions to take advantage of events in the coming weeks, carefully watching for value within equities boasting established pipelines and excellent growth prospects.

Equity Markets has reviewed Regeneron Pharmaceuticals, Inc. as a biopharmaceutical company. Regeneron discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. As of December 31, 2010, the Company had one marketed product: ARCALYST (rilonacept) injection for subcutaneous use, which is available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. The full research report on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is available here: www.EquityMarketsInc.com/researchfile4634.php.

Equity Markets is covering AstraZeneca plc as a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. The full research report on AstraZeneca plc (NYSE: AZN) is available here: www.EquityMarketsInc.com/researchfile4891.php.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information